20 June 2018 - - Beerse, Belgium-based Johnson and Johnson (NYSE: JNJ) subsidiary, Janssen Pharmaceuticals, has released results from the MERCURY PE study, which showed that people with low-risk pulmonary embolism (PE) treated with Xarelto (rivaroxaban) and discharged from the emergency department had significantly reduced time in the hospital and a median savings of USD 2,496 in per patient costs, compared to standard of care in-patient treatment, the company said.
Patients with low-risk PE were randomly assigned in a 1:1 ratio to open label Xarelto or standard of care within 12 hours of diagnosis. Patients randomised to Xarelto were discharged from the emergency department within 24 hours and were instructed to take Xarelto at the prescribed amount.
Patients randomised to standard of care were treated per local hospital protocol, which could include hospitalization and any US Food and Drug Administration-approved anticoagulant strategy, including Xarelto.
MERCURY PE met its primary efficacy endpoint, with Xarelto leading to significantly reduced time in the hospital due to VTE or bleeding within 30 days after randomization compared with the standard of care. The mean difference of length of stay between the two groups was 28.8 hours.
The Janssen Pharmaceutical Companies of Johnson and Johnson work to find new and better ways to prevent, intercept, treat, and cure disease.